Most Recent
Blooms the Chemist can't overturn a decision from the Pharmacy Council of NSW blocking the registration of a chemist, with a judge finding there was no evidence Blooms would not have a financial interest in the business.
The Victorian Supreme Court has granted cosmetic surgeon Daniel Lanzer an extension to provide discovery in a class action against him and his clinic after hearing he was facing medical issues.
Construction PRO
The competition regulator is seeking to intervene in Mayfield Development's appeal to the High Court in a case the developer says could have "startling" consequences.
Having lost a challenge to privatisation agreements by NSW Ports, the competition regulator wants to intervene in a High Court appeal by Mayfield Developments, which failed in its own case against the port authority.
Former barrister Norman O’Bryan has lost his bid to suppress reporting on the hearing where he was committed to stand trial for criminal offences related to his role in the Banksia class action, with a magistrate finding the orders would be “futile”.
Former senior barrister Norman O’Bryan has pleaded not guilty to two criminal charges in connection with his role as counsel for the Banksia Securities class action.
Construction PRO
A judge has largely given the go-ahead to Buildcorp Group's proposed amendments to cross-claims as trial gets under way in a case over aluminium cladding at Star Entertainment's Sydney casino.
Construction PRO
The High Court has approved the imposition of additional land tax on non-residents and foreign-owned entities, finding that the Commonwealth government had the power to limit the application of international tax agreements.
The High Court has upheld a decision to refuse a visa for conservative US commentator Candace Owens, finding the Migration Act's character test did not infringe on the Constitution's implied freedom of political communication.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.